Extended Data Fig. 3: Mass spectrometry analysis of TMEM106B, APP, TAF15 and FUS in insoluble extracts from individuals with FTLD-FET.
From: TAF15 amyloid filaments in frontotemporal lobar degeneration
Peptides identified by mass spectrometry are mapped along the protein sequences of TMEM106B, the amyloid-β precursor protein (APP), TAF15 and FUS. The amyloid filament core regions of TMEM106B and TAF15, as well as the Aβ42 peptide, are highlighted in yellow. Peptides from TMEM106B were not detected for individual 1, in agreement with the cryo-EM data. Peptides from Aβ42 were only detected for individual 4, in agreement with cryo-EM data and histopathology (Extended Data Table 1). Peptides mapping to the TAF15 filament core were only identified for individuals with FTLD-FET. No differences could be identified in FUS peptides for individuals with or without disease. Peptides from EWS and transportin-1 were not detected.
